株式会社 アオテアロア
HOME > 学会・研究発表 > サメ抽出脂質による悪性疾患治療

学会・研究発表

サメ抽出脂質による悪性疾患治療

2005年12月2日に韓国・釜山国立大学で開催された韓国がん予防学会年次総会で、サメ抽出脂質による悪性疾患治療の報告がありました。

2005 Annual Meeting of Korean Society of Cancer Prevention

Shark lipids for treatment of malignant diseases

Satoru Furukawa / Heimat Co., Ltd. Tokyo, Japan

Summary

Angiogenesis refers to the formation of new blood vessels from an existing vasclulature and is a multi-step, complex and tightly regulated process. The formation of new blood vessels to provide an adequate supply of nutrients to cancer cells has been shown to be fundamental for the growth and metastasis of solid tumors beyond 1-2mm in diameter. Strategies targeting tumor angiogenesis have been a focus of intense research over the past decade and antiangiogenic agents have recently received much widespread attention. Lipid rich fraction of shark muscle, which contains high ratio of phospholipids and omega-3 fatty acids, showed potent anti-angiogenic activity both in vivo and in vitro. The mechanism of the anti-angiogenesis of the lipid rich fraction of shark muscle is likely to be multifunctional. The shark lipid inhibits the effects of angiogenic growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and transforming growth factor-beta (TGF-beta). Shark cartilage is also well-known anti-angiogenic substance and source of developing anti-cancer drugs such as Novastat. In case of the shark lipid fraction mixed with olive oil in the ratio of 1:9, anti-angiogenic activity is 100 times more potent than shark cartilage powder in vitro. The shark lipid product is likely to be beneficial for prevention and treatment of cancer, however, no clinical data of shark lipid was presented in scientific journal until today. The Second Complimentary and Alternative/Integrated Medicine Forum was held in Tokyo on November 12, 2005. The shark lipid was the major topics at the cancer forum and two clinical studies, one for very advanced cancer and the other one for psoriasis had been presented at the cancer forum. Summary of these clinical studies are described in this article.